Liver Disease Programs

About Velvio

Velvio is a preclinical-stage biotech targeting a central biological pathway, TGF-β signaling, with a proprietary LNA-gapmer antisense oligonucleotide platform. Its lead candidate, NVP-13, is designed to downregulate TGFBR2 synthesis to revert inflammation, fibrosis, and restore tissue repair, with first-in-human studies imminent in ALS. The company is pursuing high-unmet-need indications in neurodegeneration, pulmonary fibrosis, and oncology, positioning its platform technology for broad therapeutic application. Led by a small team of experienced founders, Velvio is advancing towards clinical proof-of-concept.

Therapeutic Areas